Showing results (1961-1970 of 2,694) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging studyPaul A Goepfert, Bo Fu, Anne-Laure Chabanon, et al.
The Lancet. Infectious Diseases|April 24, 2021
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Hasan S Jafri, Jean Chastre, et al.
The Lancet. Infectious Diseases|April 25, 2021
Treponema pallidum detection in lesion and non-lesion sites in men who have sex with men with early syphilis: a prospective, cross-sectional studyJanet M Towns, David E Leslie, Ian Denham, et al.
The Lancet. Infectious Diseases|August 14, 2025
Innovation in active and passive immunisation of people who are immunocompromised: a call to actionJoshua A Hill, Jim Boonyaratanakornkit, Malgorzata Mikulska, et al.
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.
The Lancet. Infectious Diseases|August 3, 2025
Global typhoid fever incidence: an updated systematic review with meta-analysisShruti Murthy, Nienke N Hagedoorn, Suzanne Faigan, et al.
The Lancet. Infectious Diseases|July 17, 2025
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled studyOnyema Ogbuagu, Jason D Goldman, Robert L Gottlieb, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases|July 12, 2025
Azithromycin mass drug administration: balancing survival benefits and risks in childrenNubwa Medugu, Ian C Michelow, Claudette Poole, et al.
The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.
Pageof 270